The optimal timing and courses of bevacizumab added to chemotherapy for non-squamous non-small cell lung cancer: revelations from the real-world experience in a single Chinese cancer center

BACKGROUND: Bevacizumab combined with platinum-based chemotherapy has been approved in the first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) without driver genes, but this regimen for second-line or later-line treatment of non-squamous NSCLC remains to be further test...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Qianqian, Feng, Yu, Liu, Chang, Wu, Xianghua, Wang, Huijie, Yu, Hui, Zhao, Xinmin, Wang, Jialei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661884/
https://www.ncbi.nlm.nih.gov/pubmed/33209891
http://dx.doi.org/10.21037/atm-20-6327

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661884/
https://www.ncbi.nlm.nih.gov/pubmed/33209891
http://dx.doi.org/10.21037/atm-20-6327

Ejemplares similares